by Karyn Kaplan The current standard of care for HCV is pegylated interferon (PEG-IFN) and ribavirin. Yet in most countries, this treatment is unaffordable to all but the wealthiest people. In order to stimulate price reductions and increase access, Médecins…
by Tracy Swan It is difficult not to be dazzled by cure rates of up to 100% from interferon-free hepatitis C virus (HCV) trials presented at the American Association for the Study of Liver Diseases (AASLD) meeting in November 2012…
Grief Is a Sword: A Eulogy for Spencer Cox; A Global Plan to End AIDS Everywhere but at Home ; On the Edge: Uncertainty Grows over HIV Budgets; Data Deluge at AASLD; Beyond ARVs: Advocacy for Non-AIDS Disease Management; TB Zeroes Campaign Achieves Big Win; TAG Welcomes the FDA Approval of the First New Drug for TB in 40 Years; Help Support Inclusion of Pegylated Interferon on the World Health Organization’s Essential Medicines List; Guide to Clinical Trials for People with Hepatitis C.
There are many new hepatitis C drugs being studied in clinical trials. People with hepatitis C have many options to choose from. Whether you have hepatitis C or another medical condition, deciding to participate in a clinical trial can be complicated.
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
TAG at 20 – Part II: On a Darkling Plain—The Years of Despair; Only Stronger U.S. Leadership Can End the AIDS Epidemic; Cure-Related Research at AIDS 2012; The Future of TB in the United States: Going, or Growing?; Getting to Zero—Join the Movement!; GeneXpert Rapid TB Test Price Reduced in Historic Agreement
In 2012, the Fulbright Association presented its J. William Fulbright Prize for International Understanding to Médecins Sans Frontières (MSF); the first time this was awarded to an organization, not an individual. Treatment Action Group’s executive director, Mark Harrington, delivered this…
Letter from TAG and civil society organizations undersigned grassroots civil society groups and non-governmental organizations asking for universal access to HCV voluntary testing and treatment.
On the eve of the XIX International AIDS Conference in Washington, D.C., a new report by HIV i-Base (U.K.) and Treatment Action Group (TAG) (U.S.) reveals the deepening gulf between new scientific advances that make it possible to prevent, treat, and in some cases cure people living with HIV, hepatitis C virus (HCV), and tuberculosis (TB), and access to these where they are most needed.
HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development By Polly Clayden, Simon Collins, Colleen Daniels, Nathan Geffen, Mark Harrington, Richard Jefferys, Coco Jervis, Karyn Kaplan, Erica Lessem, and Tracy Swan.
The Research in Action Awards are on Thursday, October 15 from 6-9 p.m. at The Angel Orensanz Foundation, 172 Norfolk St., in the Lower East Side. TAG’s premier fundraising event honors the brightest scientists, activists, and artists working to end HIV, TB, and HCV.
Learn more and buy tickets now!
